



# Author Reference Guide for Annual Meeting Abstracts

DECEMBER 6-9, 2025  
ORLANDO, FLORIDA

---

HEMATOLOGY.ORG

#ASH25







The 67th ASH Annual Meeting and Exposition will be held Saturday, December 6, through Tuesday, December 9, 2025, in Orlando, Florida. The meeting will be in person, with a virtual attendance option, however, presenting authors are expected to be onsite in Orlando. The goal of the ASH annual meeting is to present the best new basic, translational, clinical, and epidemiological research in all areas of hematology. The meeting content will also be accessible to virtual meeting attendees via the virtual meeting platform.

All abstract submissions must be made electronically through ASH's online abstract submission system. The site opens on Thursday, May 29, 2025, and the abstract submission deadline is Tuesday, August 5, 2025, 11:59 p.m. Pacific time.

# Table of Contents

|   |                  |
|---|------------------|
| <b><u>Important Dates</u></b>                           | <b><u>4</u></b>  |
| <b><u>Eligibility</u></b>                               | <b><u>4</u></b>  |
| <b><u>Responsibilities of the Presenting Author</u></b> | <b><u>5</u></b>  |
| <b><u>Abstract Policies</u></b>                         | <b><u>6</u></b>  |
| <b><u>Copyright and Ownership</u></b>                   | <b><u>8</u></b>  |
| <b><u>Abstract Submission Guidelines</u></b>            | <b><u>10</u></b> |
| <b><u>How to Submit an Abstract</u></b>                 | <b><u>13</u></b> |
| <b><u>Contact Information</u></b>                       | <b><u>17</u></b> |



# Important Dates

|   |  |
|---|--|
| Abstract submission site opens              | May 29, 2025, 9:00 a.m. Eastern Time         |
| Abstract submission deadline                | August 5, 2025, 11:59 p.m. Pacific time      |
| Abstract withdrawal deadline                | September 16, 2025, 11:59 p.m. Pacific time  |
| Call for late-breaking abstract submissions | October 15-29, 2025, 11:59 p.m. Pacific time |
| Abstracts available online                  | November 3, 2025, 9:00 a.m. Eastern time     |
| Abstract poster presentation materials due  | November 10, 2025, 11:59 p.m. Pacific time   |
| Late-breaking abstracts available online    | December 1, 2025, 9:00 a.m. Eastern time     |

## Eligibility

The following criteria must be met for abstract submission:

- At least one of the authors must be a current ASH member with up-to-date payment of membership dues.
- If none of the abstract authors is an ASH member, the abstract must be sponsored by a current ASH member. ASH members are urged to use their best judgment in restricting sponsorship to a reasonable number of abstracts, keeping in mind that they are endorsing the authenticity and quality of each abstract that they sponsor.
- The content of the abstract must fit into one of the [ASH 2025 Abstract Review Categories](#).
- In contrast to past years, oral abstracts and poster presentations will no longer be contained in the ACCME-accredited portion of the annual meeting. Therefore, presenting authors are no longer subject to ACCME restrictions, and can be employees of publicly-traded or privately-held healthcare companies or owners of privately-held entities. All relevant conflicts of interest must be disclosed, and data presented fairly and transparently.

Any of the following criteria will make an abstract **ineligible** for presentation at the 2025 ASH annual meeting:

- Data from peer-reviewed content is publicly

available via major search engines (such as PubMed, Google Scholar, etc.)

- Data are accepted for journal publication before the ASH abstract submission closing date, August 5, 2025. Any abstract submission accepted for publication before August 5, 2025, must be withdrawn. Authors must notify ASH if, after the August 5th submission deadline, the work submitted is accepted for journal publication and will be published online or in print before the ASH annual meeting. In this instance, authors must request a delay in publication and refrain from posting on a preprint publication portal for accepted papers. ASH will strive to coordinate the publication with your presentation as well as any potential press releases.
- Identical or virtually identical data have been or are to be presented at a meeting of 3,000 or more participants before the 2025 ASH annual meeting. Updated analyses of work previously presented at ASH or other meetings of more than 3,000 participants will be considered only if the abstract is a significant extension of previously presented work. The author must provide an explanation documenting the significant new information. Failure to disclose prior presentation may result in rejection of the abstract.
- Artificial Intelligence was used in the generation of abstract text (see below under Abstract Policies for more details).
- Data are to be presented at an ASH Friday Satellite Symposium, scheduled for December 5, 2025.






unless otherwise specified under the **Contact Information** tab of the submission site.

- The presenting author must be one of the co-authors of the abstract.
- The presenting author is responsible for:
  - Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to obtain approval from all authors will result in rejection of the abstract;
  - Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ASH;
  - Ensuring all co-authors provide conflict-of-interest disclosures and copyright transfer documentation;
  - Forwarding all correspondence from ASH to all co-authors, including ASH policies and guidelines on the disclosure of financial relationships.

## Abstract Preprint Criteria

- Abstracts describing work posted to a preprint server before submission to ASH will be considered but preprint posting must be disclosed, and a link to the preprint provided. \*Preprints are not accepted for late-breaking submissions.
- Authors must own all copyrights in the abstract so that it may be transferred to the American Society of Hematology if the abstract is accepted, per [ASH's copyright policy](#).
- Once the abstract has been submitted to ASH, no further changes can be made to the preprint or the abstract, and the preprint may not be updated if the abstract is accepted for presentation at ASH.
- Upon abstract acceptance for presentation at the annual meeting, the content and conclusions of the abstract are embargoed from publication and must adhere to [ASH's Annual Meeting Embargo Policy](#).

- Presenting authors of abstracts accepted for oral or poster presentation must attend the 2025 annual meeting in person in Orlando. The presenter can be changed on the Author(s) tab of the submission site until August 5, 2025, 11:59 p.m. Pacific time. After this deadline, if a presenting author is unable to attend or needs to be replaced by a co-author who can attend the meeting in person, please notify [ASHabstracts@hematology.org](mailto:ASHabstracts@hematology.org) immediately.



## Responsibilities of the Presenting Author

- Once an abstract is accepted, the presenting author is the sole contact for all correspondence regarding the abstract,



- If your clinical trials abstract containing any clinical results is accepted for oral or poster presentation, ASH requests that presentations include relevant demographic information, when available, about the participants in those clinical trials. Demographic information such as sex, race, ethnicity, age, disability, or other relevant factors of the subjects enrolled in the clinical trials strengthens the science as it is important to ensure that the characteristics of the trial population adequately reflects the broader population at risk for the disease under investigation. If some or all relevant demographic information is not available, poster and oral presenters should disclose in their presentations the limitations that led to such data not being collected in the trial.

## Authors' Consent and Waiver of Claims

Each abstract author agrees and certifies that they:

- Have read all the rules and agree to be bound by them;
- Are responsible for the submission of the

abstract in accordance with ASH's the rules; and

- Waive any and all claims against ASH and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.

## Abstract Policies

- An abstract must include primary new scientific, clinical, meta-analytic, health outcomes, or epidemiologic data. The only exceptions are [Trials in Progress abstracts](#) (see the [Trials in Progress section](#) for information on criteria for a TiP abstract).
- Machine learning (ML) and Artificial intelligence (AI) tools, such as Chat GPT, are not eligible for authorship. Authors remain responsible for the originality of their work.
- Generation of original text using AI tools is prohibited. Prompts entered into an AI system by humans to generate purely AI text is prohibited, even if then reviewed by the author. In the development of original



text, AI may be used but limited to spelling and grammatical checks using a closed AI system. AI may also be used to revise existing text with human author oversight.

- ASH expects all scientific research submitted or presented as part of the abstract program to conform to the generally accepted standards of scientific integrity regarding experimental design, data collection, analysis, and interpretation.
- All studies reported in submitted abstracts involving human and animal subjects must comply with the guiding principles for experimental procedures found in the [Declaration of Helsinki](#) of the World Medical Association.
- Data from long-term follow-up or additional accrual to previously presented or published clinical trials may be submitted only if the abstract includes significant new information. In this case, authors must use the **Updated Analysis** section of the abstract form to explain the extent and the significance of new data. The reviewers will have this information available during their evaluation.
- Interim analysis of a prospective randomized clinical trial will be considered for presentation only if such an analysis is performed as planned in the original protocol or results from the trial being closed early due to unexpected toxicity, futility, or benefit. If your abstract involves interim analysis, use the **Interim Analysis of a Clinical Trial** section of the abstract form to explain the details of the study. The reviewers will have this information available during their evaluation.

#### Editorial Policy Regarding Machine Learning (ML) and Artificial Intelligence (AI) Tools:

- Text generated by AI may not be included in the abstract.
- ML/AI tools are not eligible for authorship, and may not be listed as an author.
- Research that used ML/AI tools for data acquisition or analysis is eligible for submission.

## Trials in Progress

Abstracts of Trials in Progress (TiP), i.e., descriptions of trials that have not reached the primary endpoint and [cannot](#) include any clinical data, are eligible for submission to the ASH annual meeting. TiP abstracts are expected to provide investigators

with opportunities to discuss planned and ongoing clinical trials with other clinical and industry investigators, hematologists interested in referring patients, translational researchers, statisticians, and regulators. The TiP poster platform will help increase the visibility of ongoing clinical trials, and ultimately facilitate patient recruitment.

TiP submissions will [only](#) be considered for poster presentation and will be designated as TiPs in the poster hall. TiPs will be selected for poster presentation by dedicated review panels only considering the pool of submitted TiP abstracts. Any abstract submitted as a TiP that contains clinical endpoint or other clinical data will be immediately withdrawn from consideration. Thus, abstract authors should submit abstracts containing any interim clinical trial results as regular abstracts, NOT as TiPs.

In addition to the regular eligibility criteria listed above, TiP abstracts must fulfill the following criteria:

- The trial described must fit into one of the ASH [2025 Abstract Review Categories](#).
- The clinical trial registration number (with [ClinicalTrials.gov](#) or another accepted clinical trials registry) must be provided in the abstract.



- Clinical studies submitted as TiP abstracts must be in the study design phase, or if active or ongoing, should NOT have reached the clinical endpoints for analysis. All phases of clinical research interventional studies (phases I to III, supportive care, nonpharmacologic interventions) may be considered as a TiP submission.

A TiP abstract submission should include:

- **Background and Significance:** TiP abstracts should contain the scientific rationale for the trial to be presented, for instance, information on preclinical studies as well as previously published clinical data that informed and helped guide the development of the current study.
- **Study Design and Methods:** The study design should highlight any innovative features of trial design, analytic methodologies, or study drugs and/or treatment modalities. It must include:
  - A clinical trial registration number as detailed above;
  - A description of the study population;
  - General location of participating centers (single center, or if multicenter, whether a single country, region or worldwide);
  - Major inclusion and exclusion criteria;
  - Statistical methods;
  - Biomarker selection or companion diagnostics (if appropriate); and
  - Study treatment and relevant primary and other endpoints.

The abstract must not contain any clinical endpoint data but may contain information on regulatory issues, experience with recruitment, current recruitment status, patient characteristics, and/or changes in inclusion and/or exclusion criteria or study design.

## Content Embargo

Abstracts submitted to ASH are embargoed from the time of submission. This means that the data in the abstract cannot be published in a journal once submitted for the ASH annual meeting until the meeting has concluded. (The exception for abstracts submitted to other meetings is described in the [Eligibility](#) section.) Read the [Annual Meeting Embargo Policy](#) for more details.

## Conflict-of-Interest Disclosure

ASH is committed to ensuring the integrity of its scientific, educational, and research programs. The ASH Conflict-of-Interest Policy requires disclosure of any financial or other interest in the biomedical industry that might be construed as resulting in an actual, potential, or apparent conflict, regardless of the relationship's pertinence to the abstract, or abstracts if the author is associated with more than one abstract submitted to ASH.

By completing this section of the online abstract submission, the submitter agrees that they have read the [ASH Conflict-of-Interest Policy](#) and understand and support its intent.

## Copyright and Ownership

### Abstract Copyright Transfer

Authors assign copyright of the submitted abstract to ASH upon submission, unless one of the authors is a U.S. Federal employee (in such cases, ASH does not hold copyright). This means that the identical abstract may not be republished or submitted to another meeting.

### Reuse of Abstracts

Abstracts submitted to the 67th ASH annual meeting and Exposition are copyrighted by the American Society of Hematology and published in a supplemental issue of the *Blood* journal. Other than the rights specifically granted to abstract authors (see below), any reproduction, distribution, or transmission of the abstracts in whole or in part, by electronic, mechanical, or other means, or other intended use, is prohibited without the expressed





written permission of ASH.

## Rights Granted to Abstract Authors

ASH grants each abstract author the following royalty-free rights, subject only to the acknowledgment of ASH's copyright and to the author's compliance with the ASH annual meeting embargo policy:

- Reprinting the abstract in print collections of the author's own writing;
- Reproducing the abstract for use in courses the author is teaching. If the author is employed by an academic institution, that institution may also reproduce the article for course teaching;
- Distributing photocopies of the abstract to colleagues for non-commercial purposes;
- Posting a copy of the abstract on the author's personal website, departmental website, and/or the university intranet (a hyperlink to the abstract on the *Blood* website must be included);
- Presenting the abstract orally in its entirety for non-commercial purposes (subject to compliance with the ASH annual meeting's [embargo policy](#)); and
- Using the abstract in theses and/or dissertations.

## Ownership of Presentation Materials

Materials presented at the ASH annual meeting or requested for submission by ASH in conjunction with the annual meeting, other than abstracts, including but not limited to posters, on-screen presentations (e.g. PowerPoint slides, pre-recorded presentations), and hand-outs are the

intellectual property of such individual authors and/or presenters or entities other than ASH. Although ASH is not the copyright holder of such other presentation materials, Presenters grant an exclusive license to ASH to use such other materials in connection with the presentation (see [Licensing Agreement for Presentation Materials](#) below). Presenters acknowledge and agree that any reuse of such presentation materials requires prior written permission from ASH for its reuse by the Presenter or third parties (see [Reuse of Other Presentation Materials](#) below). Authors acknowledge and agree that if they are employed by commercial entities or their studies were sponsored by commercial entities, the Author may not license or permit their works to be used by these entities without permission from ASH.

## Licensing Agreement for Presentation Materials

By presenting at the ASH annual meeting, the Presenter: (a) certifies that they hold the copyright to the presentation materials or have obtained appropriate authorization from the copyright holder to use, and to permit ASH to use, the presentation materials; and (b) grants ASH "the exclusive right to record, broadcast, create plain language summaries, and otherwise use in all media, the presentation, and all documents (including slides) displayed or distributed in connection with the presentation (collectively, the "Work"), as well as the right to use the presenter's name, likeness, voice, and biographical information in connection with the Work.

## Reuse of ASH Annual Meeting Materials

The ASH annual meeting and Exposition is convened to present the best new basic, translational, clinical, and epidemiological research in all areas of hematology. Material presented at the annual meeting is subject to copyright or other reuse restrictions. Information about these restrictions and guidelines on ASH's reuse policies are detailed below and [here](#).

Authors reusing their own material in the above ways must include appropriate attribution and do not need to contact *Blood* for permission but must comply with the annual meeting embargo policy. For all other uses, the author must request permission by visiting the [Copyright Clearance Center](#).

Any reproduction of the abstract in whole, or in part, must be accompanied by an acknowledgement



of ASH's copyright in the following form:  
© American Society of Hematology (Year). Reused with permission.

Non-authors or other entities must obtain written permission to republish any parts of works owned by ASH prior to usage (see the "Permission to Reuse" section below).

## Reuse of Other Presentation Materials

Pursuant to the rights granted exclusively to ASH, written permission from ASH is required to use the presentation and any related materials contained in, or distributed in connection with, that presentation in any media.

## Obtaining Permission to Reuse

ASH expects that all (commercial and individual) annual meeting participants will respect its intellectual property rights and use its material solely as permitted by Sections 107 and 108 of the U.S. Copyright Law (Fair Use).

For permission to use an ASH annual meeting abstract or abstract-related material beyond what is permitted by Sections 107 or 108 of the U.S. Copyright Law, please visit the [Copyright Clearance Center](#).

## Abstract Submission Guidelines

### Submission

No revisions to the abstract content can be made after the abstract submission deadline (August 5). This includes changes to the spelling of authors' names and the order of co-authors. Please proofread your abstract to ensure that it does not contain spelling, grammar, or scientific mistakes, as

it will be reproduced exactly as submitted.

- Abstracts should be written in clear and concise English so that reviewers can focus solely on the scientific merits of the submission. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling before submission.
- During online submission, you must indicate whether you prefer to have your abstract withdrawn if it is accepted as "publication-only". Abstracts may not be withdrawn after September 16, 2025. In other words, after submission authors may not request to have their abstract withdrawn because it was not selected for oral or poster presentation. Unless the author opts for automatic withdrawal at the submission stage should the abstract be selected for publication-only, the abstract will be published.
- There is an \$85 nonrefundable handling fee for each abstract submission. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted. The abstract submission fee does not include registration for the annual meeting; therefore, all authors planning to attend the ASH annual meeting must register for the meeting.
- During submission, ASH staff are authorized to communicate only with the presenting or corresponding author. Notifications of whether an abstract has been accepted will be sent to the presenting author by late September 2025. After acceptance, ASH staff will communicate only with the presenting author regarding any abstract-related matters, including requests for withdrawal, which must be submitted in writing. Any queries or requests from co-authors or non-authors, including pharmaceutical companies or medical communications companies, must go through the presenting author. Any attempts to contact ASH directly by such individuals will not be responded to.

## Presentation Format

- During submission, the authors may elect to have their abstract considered for a "poster-only" presentation. By making this selection, your abstract will not be considered for oral presentation, regardless of the score. Choose this option if you are unwilling or unable to give an oral presentation in





English. This choice must be made during the submission process and cannot be changed after the Review Committee has reached its decision.

- Depending on the number of submissions and the space constraints at the venue, ASH may not be able to accommodate all qualified submissions for an oral or poster presentation. In such a case, the submission may be accepted and designated as “publication-only.” Publication-only submissions will be published in the online-only issue of *Blood* (which is part of the permanent *Blood* archive) but will **NOT** be scheduled for presentation at the annual meeting, nor will they be featured in the web program, the annual meeting app, or the virtual meeting platform. During submission, the author must indicate if they want to have the abstract withdrawn if it is accepted for publication-only. If the publication-only option is selected, the presenting author will be notified by early October as to whether their abstract has been withdrawn due to being selected for publication-only.

## Presentation

The presentation at the annual meeting must reflect the content of the submitted abstract. In particular, the abstract title, authorship, and scientific content of the presentation must match the submitted abstract, although updated results may be included.

Abstracts cannot be changed after the submission deadline (August 1) and may not be withdrawn after September 16, 2025.

## Presentation Materials and Guidelines

ASH requires that **ALL** poster presenters submit **BOTH** a PDF of their poster and a pre-recorded, 3-to-5 minute narrated PowerPoint presentation (oral presenters are not required to submit a presentation ahead of time). The MP4 file will be included in the virtual meeting platform, and the PDF file will be printed and displayed onsite in the poster hall and included in our e-poster library. The deadline for submission of pre-recorded presentations, PowerPoint slides, and posters is November 10, 2025.

Posters that are not uploaded by November 10 will be marked “unavailable” on the virtual platform and will NOT be printed or hung by ASH. Therefore, it will be the presenting author’s responsibility to print the poster and bring it to the meeting themselves.

Pre-recorded MP4 presentations that are not uploaded by November 10 will be marked “unavailable” on the virtual meeting platform.

Presenters are expected to be standing in front of their posters to answer questions during their assigned poster presentation time.

## Abstract Review and Selection

- After the submission deadline, all completed and eligible abstracts will be made available to the ASH abstract reviewers for anonymized review and scoring, and final decisions will be made by the Review Committee in late September 2025.
- Abstracts will be evaluated and scored solely on their scientific merits. Trial in Progress abstracts will be flagged and reviewed by dedicated TiP review panels (based on the novelty of the methodology, quality of the study design, and interest to the hematology community).
- The same study must not be submitted as multiple abstracts. Abstracts that are simply different versions of a single study will be rejected.
- Abstracts will be peer-reviewed according to the subject categories. Authors must indicate the appropriate **review category** (one only) during online submission. Please use the list of updated abstract review categories when selecting the abstract classification. Read through all the categories and select the category most closely associated with your abstract. Authors will not be able to reclassify their abstracts after the abstract submission site closes. The ASH Secretary may move abstracts between categories as deemed appropriate; however, abstracts submitted to an inappropriate category may be scored in that category and are often ranked poorly. Note that major changes in abstract category content and abstract category numbering have been made this year. Please read ALL category descriptions in detail before choosing a submission category.

## Placement of Abstract in Annual Meeting Program

- **The Plenary Session** features six of the highest-scored abstracts submitted to the annual meeting and chosen by the ASH Program Committee for their quality, significance, and general interest. These abstracts are introduced in the Plenary Session by an ASH member selected to place the abstract in context for a general

hematology audience, followed by the author's presentation and a brief discussion. Failure to submit a presentation for plenary abstract by November 10 will result in the removal of presenting privileges and be noted as "Presentation Not Available" in meeting materials.

- **Oral (simultaneous) Sessions** consist of 10-minute oral abstract presentations followed by a 5-minute discussion.
- **Poster Sessions** allow in-person viewing of a poster illustration of the abstract. Presenters are expected to be at their posters to answer questions during their assigned poster presentation time. The author's attendance during the poster presentation will be monitored.

## Acceptance/Rejection Notification

- Notification regarding acceptance or rejection of abstracts will be sent via e-mail to the presenting authors in early October; consequently, providing an accurate e-mail address at submission is critical. If your abstract is accepted, the e-mail will specify whether it is accepted as a plenary, oral, or poster presentation or whether it will be published online only, without a presentation. If the presenting author has not received an e-mail notification by



October 6, 2025, contact [ASHabstracts@hematology.org](mailto:ASHabstracts@hematology.org).

- To ensure that you can receive e-mail correspondence from ASH, please make sure that your e-mail software can receive mail from the confex.com and hematology.org domains. You should add [ash@confex.com](mailto:ash@confex.com) and [ASHabstracts@hematology.org](mailto:ASHabstracts@hematology.org) to your Safe Senders list and/or address book. If after completing your submission you don't receive a confirmation e-mail from the abstract system, you must contact your system administrator and make sure that both the confex.com and hematology.org domains are added to your permitted e-mail address list.
- The decision of the ASH Program Committee regarding the acceptance and presentation of abstracts is final.

## Abstract Withdrawal

- Once an abstract has been accepted, a written request to withdraw must be submitted no later than September 16, 2025, to [ASHabstracts@hematology.org](mailto:ASHabstracts@hematology.org) by the designated presenting or corresponding author to withdraw the abstract for any reason. Abstracts will not be withdrawn after this deadline. No person other than the presenting author may contact ASH to request a withdrawal. The submitting author must ensure that all authors are aware of this policy and agree to honor it.
- ASH reserves the right to withdraw abstracts that violate the Society's policies and guidelines, such as those that have been previously published or presented, have been deemed scientifically unsound, or have been found to include inaccurate data, etc.
- If you indicated at submission that you wish to withdraw your abstract if it is not accepted for presentation, it will be withdrawn, and the presenting author will be notified; you do not need to request a withdrawal.

## Abstract Cancellation

If after the September 16 withdrawal deadline, the presenting author of a poster is unable to attend the meeting in person and a co-author cannot be identified to replace the presenter, the author should submit a request to [ASHabstracts@hematology.org](mailto:ASHabstracts@hematology.org) to cancel the presentation. A poster cancellation means that a "canceled" sign will be hung on your assigned poster board on the presentation date. The abstract will remain published in the virtual program, mobile app, and



*Blood* supplement.

## Publication in the Abstracts Supplement of *Blood*, a Journal of the American Society of Hematology

- All abstracts accepted for presentation (plenary, oral, and poster) at the ASH annual meeting are published in a special online-only supplement of *Blood*, ASH's official journal, on the [Blood Abstracts website](#).
- Abstracts selected for publication-only will be published online only on the [Blood Abstracts website](#). If an author does not want an abstract published if not accepted for presentation, the author must indicate that during submission. Publication permission cannot be withdrawn after abstract notification.
- ASH reserves the right not to publish abstracts that do not fit into any of the review categories, abstracts that inappropriately promote commercial interests in the biomedical industry, abstracts that are judged unethical, poorly written, or scientifically unsound, or abstracts considered inappropriate for publication for other reasons as determined by the ASH Program Committee.

## Late-Breaking Abstracts

Recognizing that the results of timely top-quality research may not always be available by the general abstract submission deadline, the ASH Program Committee offers an option for late-breaking abstracts.

- The late-breaking abstract submission site will open October 15 and will close October 29, 2025.
- During submission, authors of late-breaking abstracts will need to explain why their abstract was not ready by the regular deadline (August 5) and why it deserves to be considered late-breaking. This information will be available to reviewers.
- On average, only six abstracts will be accepted and presented in the late-breaking abstracts session on Tuesday, December 9, from 7:30 to 9:00 a.m. Eastern time. Selection for presentation is extremely competitive, with the quality and general significance of the presented late-breaking abstracts equivalent to Plenary Session or the top oral session abstracts. Case reports and interim trial results are NOT appropriate

for late-breaking abstract submission.

- There is a \$125 nonrefundable handling fee for submitting a late-breaking abstract. Payment must be made by credit card; Visa, MasterCard and American Express are accepted. Purchase orders and checks will not be accepted. The late-breaking abstract submission fee does not include registration for the ASH annual meeting; therefore, all authors planning to attend the annual meeting must register by visiting the [ASH annual meeting website](#). Late-breaking abstracts will undergo regular peer-review evaluation.
- Work already posted to a preprint server will not be considered for the late-breaking abstracts session.
- Accepted late-breaking abstracts will be published online on the [Blood Abstracts website](#).

## How to Submit an Abstract

### Important Submission Information

The abstract submission site is open May 29 - August 5, 2025.

All abstracts must be submitted by August 5, 2025, at 11:59 p.m. Pacific time.

All submissions that are deemed to be incomplete by this deadline will be rejected.

### Additional Submission Details

- Abstracts must be submitted online through the official online abstract submission system. Abstracts sent via e-mail to ASH will not be accepted.
- There is an \$85 nonrefundable handling fee for each abstract submission. Payment must be made by credit card; Visa, MasterCard, and American Express are accepted. Purchase orders and checks will not be accepted. The abstract submission fee does not include registration for the ASH annual meeting; therefore, all authors planning to attend the annual meeting must register by visiting the [ASH annual meeting website](#).
- The electronic submission system is compatible with PC Windows and Apple computers and with most browsers, including Google Chrome, Mozilla Firefox, Microsoft Edge, and Safari. The online abstract submission system will provide links for free browser downloads.

- If this is your first time submitting an abstract for the ASH annual meeting, please be sure to check the box indicating so during submission.
- Once you have submitted the title of the abstract, a draft of your abstract will be saved and you will be able to return to the site to edit and update the submission at any time until August 5, 2025, at 11:59 p.m. Pacific time. Revisions will not be accepted after the submission deadline. You will receive an e-mail with a link to your submission.
- Abstracts cannot be submitted and will not be reviewed without proper payment and completion of the **Submission Information** and **Disclosure** sections of the online abstract submission site.
- Any technical questions regarding the navigation of the submission site should be directed to [ash@confex.com](mailto:ash@confex.com). Authors should not leave submission of the abstract for the final day or hours so that ASH staff can have time to assist you with any technical problems that may arise during the submission process.

## Preparing an Abstract

### Selection of Abstract Review Category

Please refer to the list of this year's abstract review categories, which provides detailed descriptions of [each category](#) to assist you in selecting the correct abstract classification.

Note that categories are frequently redefined and renumbered; please read through each category before making your selection. Failure to carefully review categories may result in misplacement and therefore rejection or low scoring of the work.

### Contact Information

- The corresponding author must provide their name, degree, institutional affiliation, address, phone number, and e-mail address. All correspondence from ASH will be sent to the corresponding author during the submission period. If an abstract is accepted, all subsequent correspondence will be sent to the presenting author.
- If none of the abstract authors is an ASH member, the program will ask you to provide the name of the ASH member sponsoring the abstract.





## **Co-Authors**

- The names of all co-authors and their institutional affiliations must be provided. Please proofread the co-authors' names carefully.
- Changes will not be made to the spelling of authors' names, or the order of co-authors, after the submission deadline.

## **Abstract Title**

- The abstract title should be brief and clearly indicate the nature of the abstract.
- The abstract title must be in title case. Capitalize all nouns, pronouns, adjectives, verbs, adverbs, and subordinating conjunctions (e.g., as, because, although). Except for the first word of the title, lowercase all articles (i.e., the, a, an), coordinating conjunctions (i.e., and, or, nor), and prepositions, regardless of length. Also, lowercase "to" when used in an infinitive.
- Additionally, keep letters lowercase if the lowercase letters have a specific meaning, such as pH or NaCl.
- Do not put a period at the end of the title.
- Example: Somatic Mutations in Schinzel-Giedion Syndrome Gene SETBP1 Determine Progression in Myeloid Malignancies

## **Abstract Body**

- **Figures and tables are not permitted;** abstracts should be text-only. However, if the abstract is selected for oral or poster presentation, authors may include figures and tables in the presentation materials.
- Abstracts submitted for the ASH annual meeting are published in a special online-only November 2025 supplement of *Blood*. Abstracts will be typeset from the text submitted by the author without copyediting changes. It is the responsibility of the author to proofread the abstract and author list carefully.
- The entire body of the abstract must not exceed 4,500 characters including spaces. The title, authors' names, and authors' affiliations are not included in the character count.
- The body of the abstract should be pasted into the submission form.
- The abstract may be structured (i.e., divided into sections: Introduction, Methods, Results,

and Conclusions) or unstructured.

- Shared authorship (i.e., more than one first author) is not permitted.
- Do not use bold type or underline formatting. Italic type is acceptable.
- Text may be in multiple paragraphs.
- Special Greek and mathematical symbols are available in a character map within the submission system. Pay careful attention to superscripts, type case, font sizes, and special characters when copying/pasting abstract text.
- Use numerals to indicate numbers, except when beginning sentences.
- Any references should be noted as citations within the text and not as footnotes at the end of the abstract.

## **Use of Product Names**

- Non-proprietary (generic/scientific) names should be used and should be lowercase.
- If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalized. ASH reserves the right to replace proprietary names with generic names to adhere to this policy.

## **Abbreviations**

- Use standard abbreviations. Include abbreviations in parentheses immediately



after the first mention of a term or phrase.

## Abstract Awards

Each year, ASH offers the merit-based awards described below to support select trainees with high-achieving annual meeting abstracts who are chosen to present their work at the ASH annual meeting. Trainees include those who fall within one of the following categories: undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow (MD or PhD). The benefits vary by award.

### Abstract Achievement Awards

These \$500 merit-based awards are provided to trainees investigators with high-scoring annual meeting abstracts of which they are the first or senior author and presenter to defray travel expenses associated with their presentation at the annual meeting.

Recipients will be notified by email by late October. The list of award recipients will also be posted on the ASH website by November.

Winners must register for and attend the meeting in-person and present their abstract in person to receive their award.

### Outstanding Abstract Achievement Awards

These \$2,000 awards are provided to trainees with the highest-scoring abstract (in each trainee investigator category) of which they are the first-or-last author and presenter. Awardees also receive annual meeting travel reimbursement (coach airfare and two nights' hotel accommodations) in addition to the award.

The following individual awards are also part of the ASH Abstract Achievement Award program. Details for each can be found in the section on how to be considered for an Abstract Achievement Award on [our site](#).

- Mary Rodes Gibson Memorial Award in Hemostasis and Thrombosis
- ASH-Frank Toohey Abstract Achievement Award for Myelodysplastic Syndromes
- Hematology Inclusion Pathway Graduate Student Abstract Achievement Award (HIPGASAAA)
- ASH-IPIG Abstract Achievement Award for Paroxysmal Nocturnal Hemoglobinuria (PNH)
- National Partner Society Abstract Achievement Awards
  - ASH-BSH Abstract Achievement Award (Britain)

- ASH-HSANZ Abstract Achievement Award (Australia and New Zealand)

- ASH-JSH Abstract Achievement Award (Japan)

- ASH-SIE Abstract Achievement Award (Italy)

### How to be considered for an Abstract Achievement Award

To be considered, individuals must meet specific eligibility criteria for the desired award and fall within and select their trainee investigator level from one of the following trainee categories: Undergraduate Student (or Post Baccalaureate Student), Medical Student, Graduate Student, Resident Physician, or Postdoctoral (MD or PhD) Fellow. Applicants must check the appropriate box from these choices and check "Yes" to the question "Would you like to apply for the Abstract Achievement Award" during the online abstract submission process.

Applicants must also include with their abstract submission a letter from their senior investigator or program director overseeing their research. This letter must be typed on their institution's letterhead confirming their trainee investigator status. This letter should be signed by the senior investigator or program director overseeing their research, saved in PDF format, and uploaded to the online abstract submission system. In addition to the letter, the senior investigator will be asked to confirm the trainee investigator level of the applicant via email. Category designations that do not match between the presenting trainee investigator and their senior investigator may be recategorized or required to provide additional information during the abstract review process.

For the individual awards that are also part of the Abstract Achievement Award program, please visit our site <https://www.hematology.org/awards/achievement-awards> to view additional eligibility requirements and application instructions.

## Electronic Signature

Completion of all required disclosure information in the online abstract submission system serves as an agreement between ASH and the submitting author and is accepted in place of a faxed signature. It certifies the submitter's understanding of submission rules and affirms that:

1. All authors approve abstract submission and, presentation and publication of their work;
2. The author(s) transfer(s) all copyright ownership of the abstract to the American



Society of Hematology (except when one or more authors are U.S. Government employees);

3. All authors have read the [ASH Conflict-of-Interest Policy](#) and have acted in accordance with that policy;
4. The author(s) agree(s) to materially confine the presentation to information presented in the abstract if the abstract is accepted for presentation. If an author has more than one abstract accepted, each presentation will be materially confined to the information in the abstract selected for the specific session;
5. The presenting or other designated author will be available to present the abstract in person if selected for the program. The author(s) will immediately notify ASH if the presenting author must be changed;
6. The data in the abstract have not been accepted for publication elsewhere before the ASH submission deadline, nor will they be materially presented at a meeting of 3,000 or more participants before the ASH annual meeting (note the exception for abstracts submitted to other meetings in the [Eligibility](#) section). In addition, the data are not to be presented at an ASH Friday Satellite Symposium. If the data have been made available on a preprint server, all ASH policies summarized above regarding preprints have been and will be followed.
7. The author(s) are aware that the withdrawal deadline for ASH annual meeting abstracts is September 16, 2025, and understand that abstracts cannot be withdrawn after this date.

## Sample Abstract

A sample abstract is available for reference here. <https://ash.confex.com/ash/f/sampleabstract>

## Contact Information

All correspondence and questions regarding abstract submission policies or notifications should be sent to [ASHabstracts@hematology.org](mailto:ASHabstracts@hematology.org).

Any technical questions about the use of the submission site should be directed to [ash@confex.com](mailto:ash@confex.com).

ASH annual meeting Registration and Housing  
Submitting an abstract does not register you for the ASH annual meeting. To register, please visit [the annual meeting website](#).



SAVE THE DATE

# 67th ASH<sup>®</sup> Annual Meeting and Exposition

DECEMBER 6-9, 2025  
ORLANDO, FLORIDA

HEMATOLOGY.ORG

#ASH25

